These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 31634023

  • 1. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
    Ng D, Kerwin EM, White MV, Miller SD, Haughie S, Ward JK, Allan R.
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):99-107. PubMed ID: 31634023
    [Abstract] [Full Text] [Related]

  • 2. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
    Haughie S, Allan R, Wood N, Ward J.
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
    [Abstract] [Full Text] [Related]

  • 3. Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus.
    Cooper A, Parker J, Berry M, Wallace R, Ward J, Allan R.
    J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
    [Abstract] [Full Text] [Related]

  • 4. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
    Allan R, Canham K, Wallace R, Singh D, Ward J, Cooper A, Newcomb C.
    J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
    [Abstract] [Full Text] [Related]

  • 5. Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma.
    Longphre MV, Getz EB, Fuller R.
    Ann Am Thorac Soc; 2017 Feb; 14(2):182-189. PubMed ID: 27849125
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles.
    Shepherd T, Kennett M, Cooper A, Parkinson A.
    J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 8. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
    Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK.
    Pulm Med; 2021 Aug; 2021():8881895. PubMed ID: 33815843
    [Abstract] [Full Text] [Related]

  • 9. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.
    Donohue JF, Burgoyne DS, Ward JK, Allan R, Koltun A, Cooper A.
    Pulm Ther; 2021 Jun; 7(1):47-57. PubMed ID: 33284384
    [Abstract] [Full Text] [Related]

  • 10. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
    Chan R, Sousa AR, Mallett S, Hynds P, Homayoun-Valiani F, Tabberer M, Mehta R.
    Pulm Pharmacol Ther; 2016 Dec; 41():19-24. PubMed ID: 27599598
    [Abstract] [Full Text] [Related]

  • 11. A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products.
    Allan R, Haughie S, Ahrens R, Singh S, Ward J.
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):352-363. PubMed ID: 31259673
    [Abstract] [Full Text] [Related]

  • 12. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
    Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV.
    Ann Intern Med; 2023 Aug; 176(8):1047-1056. PubMed ID: 37549393
    [Abstract] [Full Text] [Related]

  • 13. A Dose-Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder.
    Allan R, Haughie S, Kerwin E, Ward J.
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):364-373. PubMed ID: 31259655
    [Abstract] [Full Text] [Related]

  • 14. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
    Sher LD, Yiu G, Sakov A, Liu S, Caracta CF.
    Allergy Asthma Proc; 2017 Sep 21; 38(5):343-353. PubMed ID: 28639542
    [Abstract] [Full Text] [Related]

  • 15. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.
    Chan R, Sousa AR, Hynds P, Homayoun-Valiani F, Edwards D, Tabberer M.
    Pulm Pharmacol Ther; 2017 Apr 21; 43():12-19. PubMed ID: 28115223
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
    Raphael G, Yiu G, Sakov A, Liu S, Caracta C.
    J Asthma; 2018 Jun 21; 55(6):640-650. PubMed ID: 28763243
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
    Mehta R, Riddell K, Gupta A, Louey MD, Chan RH.
    Clin Drug Investig; 2015 May 21; 35(5):319-26. PubMed ID: 25805608
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
    Li S, Feng K, Lee J, Gong Y, Wu F, Newman B, Yoon M, Fang L, Zhao L, Gobburu JVS.
    AAPS J; 2024 Apr 26; 26(3):56. PubMed ID: 38671158
    [Abstract] [Full Text] [Related]

  • 19. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
    Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO.
    Respir Med; 1999 Dec 26; 93(12):876-84. PubMed ID: 10653049
    [Abstract] [Full Text] [Related]

  • 20. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P, PALLADIUM trial investigators.
    Lancet Respir Med; 2020 Oct 26; 8(10):987-999. PubMed ID: 32653075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.